No profile data available.
Assembly Biosciences, Inc. (ASMB) is a healthcare company in the antiviral pharmaceuticals industry, based in South San Francisco, United States, with about 73 full-time employees.
It reported revenue of $72.30 million for fiscal year 2025, up 153.5% from fiscal year 2024, and net income of -$6.12 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $13.37 million, up 38.9% from a year before. Its market capitalization was $464.63 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 8, 2026.
, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.
Assembly Biosciences reported $72.30 million in revenue for fiscal year 2025, up 153.5% from $28.52 million in fiscal year 2024. In Q2 2026 revenue was $13.37 million.
$464.63 million as of October 8, 2026.
Listed companies of a similar size in the same industry (antiviral pharmaceuticals) include Novavax, Inc. (NVAX), Vir Biotechnology, Inc. (VIR), Valneva SE (VALN), Atea Pharmaceuticals, Inc. (AVIR).